Beacon Biosignals Completes Strategic Transaction to Acquire CleveMed

BOSTON - April 21, 2025, Beacon Biosignals, the global leader in at-home EEG and AI-powered neurotechnology, has today announced that the company has acquired CleveMed, a leader in Home Sleep Testing (HST) technology and services, in a strategic transaction that will strengthen the capabilities of both companies.

Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals commented, "There is a lot we can learn from each other to expand and enhance our service offerings, including bringing the power of Beacon Biosignals AI-driven algorithms to CleveMed's existing devices and offerings." Hani Kayyali, CEO and president of CleveMed said, "We are so excited about this opportunity.

With our fast-growing market presence and Beacon's exceptional AI capabilities, this strategic partnership is uniquely positioned to expand access to quality care while addressing future sleep testing needs".

About CleveMed

CleveMed is a fast growing company with a wide range of sleep testing equipment, services, and web-based technologies that allow sleep disorders to be monitored in the home, including SleepView® technologies, and SleepView Direct.

CleveMed's goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients' experiences in the home.

For more information, please visit www.CleveMed.com

About Beacon Biosignals

Beacon Biosignals is a neurotechnology company transforming the development of treatments for neurological, psychiatric, and sleep disorders.

Leveraging our 510(k)-cleared EEG headband, AI-driven sleep scoring algorithms, and large real-world neurophysiology datasets, Beacon accelerates insights into brain activity to improve patient outcomes.

Share this post: